Literature DB >> 23095475

Clarithromycin stops lung function decline in airway-centered interstitial fibrosis.

S Jouneau1, M Kerjouan, S Caulet-Maugendre, S Guillot, C Meunier, B Desrues, P Delaval.   

Abstract

Airway-centered interstitial fibrosis (ACIF) is a distinct type of lung interstitial fibrosis characterized by lesions centered on the airways. Several cases reported in the literature showed little to no effect of corticosteroids and a high mortality rate in the absence of lung transplantation. No other efficient approach is described for the treatment of this type of fibrosis. We report for the first time the case of a 44-year-old patient diagnosed with ACIF on surgical lung biopsy and stabilized with clarithromycin after failure of systemic corticosteroids. We need to confirm this benefit in other patients to ascertain the anti-inflammatory effect of macrolides, which are far less harmful compared to corticosteroids or immunosuppressant drugs.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23095475     DOI: 10.1159/000341982

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  2 in total

1.  Airway-centered interstitial fibrosis - an under-recognized subtype of diffuse parenchymal lung diseases.

Authors:  E Silbernagel; A Morresi-Hauf; S Reu; B King; W Gesierich; M Lindner; J Behr; F Reichenberger
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2018-04-28       Impact factor: 0.670

2.  Immunomodulatory effects of a low-dose clarithromycin-based macrolide solution pressurised metered dose inhaler.

Authors:  Mehra Haghi; Alessandro Saadat; Bing Zhu; Gaia Colombo; Gregory King; Paul M Young; Daniela Traini
Journal:  Pharm Res       Date:  2014-12-24       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.